Connect with Quotient Sciences at the upcoming BIO International Convention 2023 in Boston, MA between June 5-8.

Schedule a meeting


24 results for "Translational Pharmaceutics"

Translational Pharmaceutics®

Tufts CSDD Study Assessing the Financial Benefits of Translational Pharmaceutics®: A Platform for Accelerating Product Development

This webinar summarizes the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. Access our on-demand webinar now.

Assessing the Financial Impact of Translational Pharmaceutics®

Assessing the financial impact of Translational Pharmaceutics®

Dramatically Reduce Your Development Time and Costs with Translational Pharmaceutics®

Application of Translational Pharmaceutics® to reduce time, cost and risk in the early development of inhaled drug products - RDD

The efficiency and effectiveness of new drug development has remained problematic over the last decade. Translational Pharmaceutics has emerged as a new paradigm to improve R&D productivity.

Application of Translational Pharmaceutics® in Accelerating the Development of MR Dosage Forms

Poster presentation at NERDG 2021 Annual Meeting. In this poster we demonstrate an optimized approach to developing oral modified-release (MR) dosage forms using the Translational Pharmaceutics platform. This approach uses emerging human data to inform adjustment of formulation composition in an adaptive clinical study.

Assessing the Financial Impact of Translational Pharmaceutics®

Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.

Translational Pharmaceutics® Fact Sheet

Quotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.

AAPS 2019 Poster: A Phase I Study Allowing Clinical Screening of Multiple Solubility-Enhancement Formulation Technologies, and an Assessment of Food, PPI and Dose Linearity Assessment with the Selected Formulation of BOS172767, in Healthy Volunteers

Presented at AAPS 2019: Translational Pharmaceutics was used to evaluate three BOS172767 formulations in on a integrated clinical study, and successfully identified the micronized capsule as the new lead formulation.


DCAT Lunch Seminar: Strategies for Achieving Regulatory Milestones Faster | New York, NY

Interested in achieving your regulatory milestones faster? Save your spot at our DCAT Week lunch seminar on March 22nd!

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is taking advantage of Quotient Sciences’ Translational Pharmaceutics® platform and First-In-Human program for the development of BCX4161, a promising candidate for the treatment of hereditary angioedema.

A rapid formulation development and clinical testing program to evaluate the pharmacokinetics of a novel enabled formulation of abiraterone acetate - AAPS 2016

Following initial dosing, the Translational Pharmaceutics platform also allows GMP drug products to be made in real-time in response to interim analysis of clinical data, typically on a 7-14 day cycle.

Strategies for Achieving Regulatory Milestones Faster

Watch our on-demand webinar featuring a customer case study from Ensysce Biosciences' CEO Lynn Kirkpatrick on choosing an integrated service provider to accelerate drug development.

Strategies for Achieving Regulatory Milestones Faster | Global Webinar

Save your spot for our next webinar featuring a customer case study from Ensysce Biosciences on April 19, 2023. Dr. Vanessa Zann, Senior Drug Development Consultant, will be joined by Lynn Kirkpatrick, CEO of Ensysce Biosciences for this special presentation.


Protein kinase inhibitors (PKIs) are used in the treatment of cancer and inflammation, but food interactions are a common problem with this class of drugs. Swedish drug delivery company Xspray has used its Hybrid Nanoparticle (HyNap™) technology to improve the bioavailability of the PKI nilotinib, reducing the required dose and significantly lowering the food interaction of the drug compared with the marketed product.

MEI Pharma

MEI Pharma has leveraged Quotient's Translational Pharmaceutics® platform to expedite development of its next-generation cancer therapy ME-401.


Enhanced formulation decision-making in early phase clinical trials for parenteral products

This presentation describes the principles and applications of Translational Pharmaceutics: an R&D platform integrating formulation development, real-time adaptive GMP manufacturing and clinical testing in order to accelerate drug development cycles.

First-in-Human to Proof-of-Concept

Our Translational Pharmaceutics approach enables First-in-Human studies by re-engineering the transition of your drug molecule into clinical development and shortening the timeline to Proof-of-Concept.

The Role of Biopharmaceutics in Early Drug Development

This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.

Integrated Drug Substance & Drug Product Strategies | Garnet Valley Lunch Seminar

Save your spot for our upcoming lunch seminar at our Garnet Valley, PA facility on May 2nd entitled: "Accelerating Development Through Integrated Drug Substance & Drug Product Strategies: Fully integrated programs to shorten the clinical pathway."

Getting it Right Early: The Importance of Biopharmaceutics in Early Drug Development

Chris Roe, Quotient Sciences' Principal Research Fellow, discusses strategies for overcoming biopharmaceutic challenges for small molecules in today’s drug development.

Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.